EA035455B1 - Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов - Google Patents

Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов Download PDF

Info

Publication number
EA035455B1
EA035455B1 EA201692529A EA201692529A EA035455B1 EA 035455 B1 EA035455 B1 EA 035455B1 EA 201692529 A EA201692529 A EA 201692529A EA 201692529 A EA201692529 A EA 201692529A EA 035455 B1 EA035455 B1 EA 035455B1
Authority
EA
Eurasian Patent Office
Prior art keywords
cys
lys
ser
glu
leu
Prior art date
Application number
EA201692529A
Other languages
English (en)
Russian (ru)
Other versions
EA201692529A1 (ru
Inventor
Равиндра КУМАР
Ася ГРИНБЕРГ
Original Assignee
Акселерон Фарма, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Акселерон Фарма, Инк. filed Critical Акселерон Фарма, Инк.
Publication of EA201692529A1 publication Critical patent/EA201692529A1/ru
Publication of EA035455B1 publication Critical patent/EA035455B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4703Inhibitors; Suppressors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06Anabolic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4707Muscular dystrophy
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EA201692529A 2014-06-04 2015-06-04 Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов EA035455B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462007908P 2014-06-04 2014-06-04
PCT/US2015/034245 WO2015187977A1 (en) 2014-06-04 2015-06-04 Methods and compositions for treatment of disorders with follistatin polypeptides

Publications (2)

Publication Number Publication Date
EA201692529A1 EA201692529A1 (ru) 2017-05-31
EA035455B1 true EA035455B1 (ru) 2020-06-18

Family

ID=54767384

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201692529A EA035455B1 (ru) 2014-06-04 2015-06-04 Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
EA202090632A EA202090632A1 (ru) 2014-06-04 2015-06-04 Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA202090632A EA202090632A1 (ru) 2014-06-04 2015-06-04 Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов

Country Status (12)

Country Link
US (2) US10023621B2 (enExample)
EP (2) EP3721892B1 (enExample)
JP (3) JP6568110B2 (enExample)
KR (4) KR102077286B1 (enExample)
CN (2) CN113583104A (enExample)
AU (2) AU2015269333B2 (enExample)
BR (1) BR112016028520A2 (enExample)
CA (1) CA2950754C (enExample)
EA (2) EA035455B1 (enExample)
MA (2) MA51075A (enExample)
MX (2) MX382908B (enExample)
WO (1) WO2015187977A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58231B1 (sr) 2005-11-23 2019-03-29 Acceleron Pharma Inc Antagonisti aktivin-actriia i primene za stimulaciju rasta kostiju
EP3415161A1 (en) 2008-06-26 2018-12-19 Acceleron Pharma Inc. The use of an actriib antagonist for the treatment of anemia
CA2898121A1 (en) 2013-01-25 2014-07-31 Shire Human Genetic Therapies, Inc. Follistatin in treating duchenne muscular dystrophy
US10010498B2 (en) 2014-06-04 2018-07-03 Acceleron Pharma Inc. Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
AU2015269333B2 (en) 2014-06-04 2020-05-07 Acceleron Pharma, Inc. Methods and compositions for treatment of disorders with follistatin polypeptides
TN2016000553A1 (en) 2014-06-13 2018-04-04 Acceleron Pharma Inc Methods and compositions for treating ulcers
EP3274457A4 (en) 2015-03-26 2018-08-08 Acceleron Pharma Inc. Follistatin-related fusion proteins and uses thereof
JP2019509735A (ja) * 2016-03-04 2019-04-11 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド デュシェンヌ型筋ジストロフィー治療における組換えフォリスタチン−Fc融合タンパク質及び使用
US10905766B2 (en) 2017-03-23 2021-02-02 Oregon State University Therapeutic compositions and methods for treatment of muscle wasting diseases
KR101822633B1 (ko) * 2017-08-22 2018-01-26 (주)진셀팜 폴리스타틴 유래 생리활성 펩타이드, 및 이의 용도
WO2019046903A1 (en) * 2017-09-08 2019-03-14 Baker Heart and Diabetes Institute THERAPEUTIC METHOD FOR INCREASING MUSCLE MASS IN A SUBJECT
CN108218985B (zh) * 2017-12-12 2021-04-30 山西农业大学 一种利用特征多肽制备fst蛋白特异性抗体的方法及其应用
EP3765601A1 (en) * 2018-03-16 2021-01-20 Immusoft Corporation B cells genetically engineered to secrete follistatin and methods of using the same to treat follistatin-related diseases, conditions, disorders and to enhance muscle growth and strength
US11672845B2 (en) * 2018-03-21 2023-06-13 Soulyoung Biotech Co., Ltd. Composition for promoting local muscle growth or slowing down or preventing local muscle atrophy and use thereof
WO2019191204A1 (en) * 2018-03-28 2019-10-03 Acceleron Pharma Inc. Follistatin polypeptides for the treatment of muscle contracture
US20210207135A1 (en) * 2018-05-17 2021-07-08 Housey Pharmaceutical Research Laboratories, L.L.C. Inhibition of follistatin
WO2020046466A1 (en) * 2018-08-29 2020-03-05 Myos Rens Technology, Inc. Methods for alleviating, inhibiting or reversing muscle disuse atrophy in mammals
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
CN119654337A (zh) 2022-06-15 2025-03-18 Ucb生物制药有限责任公司 用于预防、治疗或改善肾脏疾病的融合蛋白
JP2025520393A (ja) 2022-06-15 2025-07-03 ユーシービー バイオファルマ エスアールエル フォリスタチン-fc融合タンパク質
WO2024121351A1 (en) * 2022-12-07 2024-06-13 Lodberg Andreas Extracellular matrix binding compounds for the localized loading of therapeutic or diagnostic agents
TW202530250A (zh) * 2024-01-25 2025-08-01 大陸商四川至善唯新生物科技有限公司 編碼卵泡抑素的核酸及其用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033134A2 (en) * 2003-09-30 2005-04-14 Regeneron Pharmaceuticals, Inc. Secreted protein therapeutics and uses thereof
WO2007067616A2 (en) * 2005-12-06 2007-06-14 Amgen Inc Uses of myostatin antagonists
WO2009158025A2 (en) * 2008-06-26 2009-12-30 Acceleron Pharma Inc. Methods for dosing an actriib antagonist and monitoring of treated patients
WO2013151665A2 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
WO2014116981A1 (en) * 2013-01-25 2014-07-31 Shire Human Genetic Therapies, Inc. Follistatin in treating duchenne muscular dystrophy
WO2014187807A1 (en) * 2013-05-21 2014-11-27 Arcarios B.V. Follistatin derivatives

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US5182375A (en) 1987-08-28 1993-01-26 The Salk Institute For Biological Studies DNA encoding follistatin
US5041538A (en) 1987-08-28 1991-08-20 The Salk Institute For Biological Studies Mammalian follistatin
WO1992013947A1 (en) 1991-02-08 1992-08-20 Progenics Pharmaceuticals, Inc. CD4-GAMMA2 AND CD4-IgG2 CHIMERAS
DE69310525T2 (de) 1992-09-16 1997-10-02 Genentech Inc Schutz gegen leberschäden mit hgf
US6686198B1 (en) 1993-10-14 2004-02-03 President And Fellows Of Harvard College Method of inducing and maintaining neuronal cells
ATE355369T1 (de) 1993-10-14 2006-03-15 Harvard College Verfahren zur induzierung und zur erhaltung neuronalen zellen
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5545616A (en) 1994-09-22 1996-08-13 Genentech, Inc. Method for predicting and/or preventing preterm labor
GB2306481A (en) 1995-10-21 1997-05-07 Univ Manchester Pharmaceutical comprising a stimulator of activin and/or inhibin
AU8666398A (en) 1997-08-01 1999-02-22 Johns Hopkins University School Of Medicine, The Methods to identify growth differentiation factor (gdf) receptors
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6004937A (en) 1998-03-09 1999-12-21 Genetics Institute, Inc. Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
ATE322681T1 (de) 1999-01-21 2006-04-15 Metamorphix Inc Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen
CA2365449A1 (en) 1999-04-19 2000-10-26 Kyowa Hakko Kogyo Co., Ltd. Inhibitor of the growth of androgen-independent tumor
WO2001009368A1 (en) 1999-07-30 2001-02-08 The General Hospital Corporation Follistatin antagonists
JP4487376B2 (ja) 2000-03-31 2010-06-23 味の素株式会社 腎疾患治療剤
AUPR638101A0 (en) 2001-07-13 2001-08-09 Bioa Pty Limited Composition and method for treatment of disease
WO2003072715A2 (en) 2002-02-21 2003-09-04 Wyeth Gasp1: a follistatin domain containing protein
CN1993048A (zh) * 2002-02-21 2007-07-04 惠氏公司 包含促滤泡素抑制素结构域的蛋白质
AU2003216345A1 (en) 2002-02-21 2003-09-09 Wyeth Follistatin domain containing proteins
WO2004082710A1 (en) 2003-03-21 2004-09-30 Lorantis Limited Treatment of allergic diseases using a modulator of the notch signaling pathway
KR20060026860A (ko) 2003-06-02 2006-03-24 와이어쓰 신경근 장애의 치료를 위한, 코르티코스테로이드와 조합된미오스타틴 (gdf8) 저해제의 용도
US20070135336A1 (en) 2003-09-15 2007-06-14 De Kretser David Follistatin isoforms and uses thereof
JP2007507429A (ja) 2003-10-06 2007-03-29 モナシュ ユニバーシティー 治療方法
JP4688483B2 (ja) 2004-04-15 2011-05-25 株式会社テクノネットワーク四国 フォリスタチン変異体ポリペプチド
EP1771470B1 (en) * 2004-07-23 2013-06-26 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
WO2006020884A2 (en) 2004-08-12 2006-02-23 Wyeth Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
EP3327033A1 (en) 2005-08-19 2018-05-30 Wyeth LLC Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-associated disorders
WO2008030367A2 (en) 2006-09-01 2008-03-13 The General Hospital Corporation Selective myostatin inhibitors
CA2693178C (en) 2006-11-29 2018-12-04 Nationwide Children's Hospital, Inc. Myostatin inhibition for enhancing muscle and/or improving muscle function
US20100028332A1 (en) 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
MX2009006651A (es) 2006-12-18 2009-08-26 Acceleron Pharma Inc Antagonistas de activina-actrii y usos para incrementar los niveles de globulos rojo.
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
AU2009204501B2 (en) 2008-01-07 2015-02-12 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
WO2009158033A2 (en) * 2008-06-26 2009-12-30 Acceleron Pharma Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
BR112012005225B8 (pt) * 2009-09-09 2023-01-10 Acceleron Pharma Inc Uso de uma proteína de fusão actriib-fc para o tratamento de um transtorno relacionado ao osso ou associado à perda de músculo por crescimento muscular insuficiente
RU2013110874A (ru) * 2010-08-25 2014-09-27 Ф.Хоффманн-Ля Рош Аг Антитела против il-18r1 и их применения
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
AU2013262436B2 (en) 2012-05-17 2017-09-07 Paranta Biosciences Limited A method of treatment and agents useful for same
CA2876293C (en) * 2012-06-27 2023-10-10 Arthrogen B.V. Combination for treating an inflammatory disorder
AU2015269333B2 (en) * 2014-06-04 2020-05-07 Acceleron Pharma, Inc. Methods and compositions for treatment of disorders with follistatin polypeptides
US10010498B2 (en) 2014-06-04 2018-07-03 Acceleron Pharma Inc. Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
EP3274457A4 (en) 2015-03-26 2018-08-08 Acceleron Pharma Inc. Follistatin-related fusion proteins and uses thereof
WO2018209242A1 (en) 2017-05-12 2018-11-15 Shire Human Genetic Therapies, Inc. Recombinant follistatin-fc fusion proteins and use in treating duchenne muscular dystrophy

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033134A2 (en) * 2003-09-30 2005-04-14 Regeneron Pharmaceuticals, Inc. Secreted protein therapeutics and uses thereof
WO2007067616A2 (en) * 2005-12-06 2007-06-14 Amgen Inc Uses of myostatin antagonists
WO2009158025A2 (en) * 2008-06-26 2009-12-30 Acceleron Pharma Inc. Methods for dosing an actriib antagonist and monitoring of treated patients
WO2009158035A2 (en) * 2008-06-26 2009-12-30 Acceleron Pharma Inc. Methods for dosing an activin-actriia antagonist and monitoring of treated patients
US20150158923A1 (en) * 2008-06-26 2015-06-11 Acceleron Pharma, Inc. Follistatin Fusion Proteins and Uses Thereof
WO2013151665A2 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
WO2014116981A1 (en) * 2013-01-25 2014-07-31 Shire Human Genetic Therapies, Inc. Follistatin in treating duchenne muscular dystrophy
WO2014187807A1 (en) * 2013-05-21 2014-11-27 Arcarios B.V. Follistatin derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Datta-Mannan A. et al. "An Engineered Human Follistatin Variant: Insights into the Pharmacokinetic and Pharmocodynamic Relationships of a Novel Molecule with Broad Therapeutic Potential" The Journal of Pharmacology and Experimental Therapeutics (2013) 344(3): 616-623 See page 617, left-hand column, last paragraph; abstract; Figure 3; page 620, right hand column; page 620, left-hand column; Figure 4; page 617, right-hand column *
Yaden B.C. et al. "Follistatin: A Novel Therapeutic for the Improvement of Muscle Regeneration" The Journal of Pharmacology and Experimental Therapeutics (2014) 349 (2): 355-371 See page 359, left-hand column, first paragraph; Figure 2; page 360, left-hand column, first paragraph *

Also Published As

Publication number Publication date
KR20170005891A (ko) 2017-01-16
KR20200084064A (ko) 2020-07-09
US20160185836A1 (en) 2016-06-30
KR20200017548A (ko) 2020-02-18
US20180340013A1 (en) 2018-11-29
EA201692529A1 (ru) 2017-05-31
WO2015187977A1 (en) 2015-12-10
MA51074A (fr) 2020-10-14
EP3152237A1 (en) 2017-04-12
JP2019203017A (ja) 2019-11-28
US10023621B2 (en) 2018-07-17
BR112016028520A2 (pt) 2017-10-24
EA202090632A1 (ru) 2020-07-31
MX382908B (es) 2025-03-13
CA2950754C (en) 2021-10-26
CN106795224B (zh) 2021-05-18
EP3152237A4 (en) 2017-11-01
MA51075A (fr) 2020-10-14
CA2950754A1 (en) 2015-12-10
CN113583104A (zh) 2021-11-02
EP3152237B1 (en) 2020-04-01
JP6568110B2 (ja) 2019-08-28
JP2021095416A (ja) 2021-06-24
AU2015269333B2 (en) 2020-05-07
JP6856716B2 (ja) 2021-04-07
KR102077286B1 (ko) 2020-02-13
JP2017518303A (ja) 2017-07-06
KR102132144B1 (ko) 2020-07-09
AU2015269333A1 (en) 2016-12-15
AU2020210315A1 (en) 2020-08-27
EP3721892B1 (en) 2024-05-22
US10954279B2 (en) 2021-03-23
KR102305109B1 (ko) 2021-09-27
MX2021006017A (es) 2021-07-06
MX2016015868A (es) 2017-04-05
CN106795224A (zh) 2017-05-31
EP3721892A1 (en) 2020-10-14
KR20210119546A (ko) 2021-10-05

Similar Documents

Publication Publication Date Title
KR102132144B1 (ko) 폴리스타틴 폴리펩티드를 이용한 장애의 치료방법 및 치료를 위한 조성물
US8138142B2 (en) Methods for increasing adiponectin in a patient in need thereof
US11497792B2 (en) Methods for treatment of Duchenne muscular dystrophy with follistatin polypeptides
EP3805259A1 (en) Truncated actriib-fc fusion proteins
CN101679505A (zh) 由actriib衍生的变体及其用途
HK1238658B (zh) 用促滤泡素抑制素多肽治疗病症的方法和组合物
HK1238658A1 (en) Methods and compositions for treatment of disorders with follistatin polypeptides
HK1236544A1 (en) Methods and compositions for treatment of disorders with follistatin polypeptides
HK1236544B (en) Methods and compositions for treatment of disorders with follistatin polypeptides

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM